Neurocrine Biosciences

Forecast & Rating29 analysts currently cover Neurocrine Biosciences, with about 86.2% giving a positive rating — meaning they expect the stock to rise. The average price target is $207.29, about 44.5% upside from the current price of $143.47. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 78.5% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Neurocrine Biosciences closely still see room for the stock to rise. Data as of Oct 5, 2026; for reference only and not investment advice.